Vertex Pharmaceuticals | VRTX - Marktkapitalisierung

Aktienkurs
423.24
Täglich Wechseln
-6.90 -1.60%
Monatlich
-4.50%
Jährlich
-16.93%
Q2 Prognose
421.08




Marktkapitalisierung Veränderung Datum
AbbVie USD 355.2B 48.64B 2026-04
Acadia Pharmaceuticals USD 4.52B 919M 2025-12
Agios Pharmaceuticals USD 1.53B 57M 2026-04
Alnylam Pharmaceuticals USD 52.54B 7.24B 2025-12
Amgen USD 176.25B 24.32B 2025-12
Arrowhead Research USD 9.02B 4.25B 2025-12
Biogen USD 27.49B 589M 2026-04
BioMarin Pharmaceutical USD 11.42B 1.02B 2025-12
Bristol-Myers Squibb USD 109.81B 18.01B 2025-12
Gilead Sciences USD 166.62B 14.34B 2026-04
Incyte USD 21.96B 3.23B 2026-04
Insmed USD 37.12B 6.68B 2025-12
Ionis Pharmaceuticals USD 10.55B 1.91B 2026-04
J&J USD 561.65B 17.5B 2026-04
Merck USD 261.26B 51.62B 2025-12
Neurocrine Biosciences USD 14.14B 218M 2025-12
Novartis USD 231.75B 76B 2026-04
Pfizer USD 141.57B 6.48B 2025-12
PTC Therapeutics USD 5.26B 844M 2026-04
Regeneron Pharmaceuticals USD 75.46B 6.22B 2026-04
Roche Holding CHF 266.34B 55.46B 2025-12
Sanofi EUR 101.43B 1.16B 2026-04
Sarepta Therapeutics USD 2.26B 238M 2025-12
Ultragenyx Pharmaceutical USD 2.22B 680M 2025-12
United Therapeutics USD 20.98B 2.02B 2025-12
Vertex Pharmaceuticals USD 115.03B 14.61B 2025-12